@article{2999665,
    title = "Infection with SARS-CoV-2 among children with asthma: evidence from Global Asthma Network",
    author = "Chiang, C.-Y. and Ellwood, P. and Ellwood, E. and García-Marcos, L. and Masekela, R. and Asher, I. and Badellino, H. and Sanz, A.B. and Douros, K. and El Sony, A. and Diaz, C.G. and Rodríguez, M.S.A. and Moreno-Salvador, A. and Pérez-Martini, L.F. and Filho, N. and Shpakou, A. and Sulaimanov, S. and Tavakol, M. and Valverde-Molina, J. and Yousef, A.A. and Pearce, N. and The GAN COVID Study Group",
    journal = "Pediatric Allergy and Immunology",
    year = "2022",
    volume = "33",
    number = "1",
    publisher = "John Wiley and Sons Inc",
    issn = "0905-6157, 1399-3038",
    doi = "10.1111/pai.13709",
    keywords = "corticosteroid, asthma;  child;  human;  pandemic, Adrenal Cortex Hormones;  Asthma;  Child;  COVID-19;  Humans;  Pandemics;  SARS-CoV-2",
    abstract = "Background: Clinical presentations of coronavirus disease 2019 (COVID-19) among children with asthma have rarely been investigated. This study aimed to assess clinical manifestations and outcome of COVID-19 among children with asthma, and whether the use of asthma medications was associated with outcomes of interest. Methods: The Global Asthma Network (GAN) conducted a global survey among GAN centers. Data collection was between November 2020 and April 2021. Results: Fourteen GAN centers from 10 countries provided data on 169 children with asthma infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). COVID-19 was asymptomatic in 58 (34.3%), mild in 93 (55.0%), moderate in 14 (8.3%), and severe/critical in 4 (2.4%). Thirty-eight (22.5%) patients had exacerbation of asthma and 21 (12.4%) were hospitalized for a median of 7 days (interquartile range 3–16). Those who had moderate or more severe COVID-19 were significantly more likely to have exacerbation of asthma as compared to those who were asymptomatic or had mild COVID-19 (adjusted odds ratio (adjOR) 3.97, 95% CI 1.23–12.84). Those who used inhaled bronchodilators were significantly more likely to have a change of asthma medications (adjOR 2.39, 95% CI 1.02–5.63) compared to those who did not. Children who used inhaled corticosteroids (ICS) did not differ from those who did not use ICS with regard to being symptomatic, severity of COVID-19, asthma exacerbation, and hospitalization. Conclusions: Over dependence on inhaled bronchodilator may be inappropriate. Use of ICS may be safe and should be continued in children with asthma during the pandemic of COVID-19. © 2021 EAACI and John Wiley and Sons A/S. Published by John Wiley and Sons Ltd."
}